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CJbjectives. We investigated 1) the feasibility, safety and efficacy 
ofmultisite right atria1 pacing for prevention of atrial fibrillation 
(Al!); and 2) the ability or atria1 pacing in single- and dual-site 
modes to increase arrhythmia-free intervals in patients with drug- 
refractory AF. 
Buc~ground. We recently developed and applied a novel tech- 
nique of dual-site right atrial pacing in an unselected group of 
consecutive patients with AF requiring demand pacing. A prospec- 
tive crossover study desigu was used to evaluate single- and 
dual-site right atriai pacing modes. 
MeUxx&. The frequency of AF during the 3 months before 
pacemaker implantation was analyzed. Consecutive consenting 
patients underwerrt iaseaion of two atria1 leads and one ventric- 
ular lead with _ DDDP purse generator, Patients were placed in a 
dual-site pacing mode for the first 3 months and subsequently 
mode switched to single site pacing for 3 months. Mode switching 
was repeated at (i-month intervals thereafter. 
Rest&s. Atria1 pacing resulted in a marked decline in AF 
recurrences (p < 0.001). During dual-site pacing with an optimal 
Atria1 fibrillation (AF) and flutter have the highest prevalence 
rates of all cardiac arrhythmias. Therapeutic control has been 
generally diflicult. Despite widespread application of antiar- 
rhythmic drug therapy, arrhythmia recurrence is common, 
accounting for repetitive hospital admissions for modification 
of antiarrhythmic regimens, anticoagulation and electrical 
cardioversion. In many reports, up to 50% of patients may 
experience a relapse during a given drug regimen within 1 year 
(1). Transthoracic and, more recently, internal atria1 defibril- 
lation shocks have been used for arrhythmia termination (2,3), 
Defibrillation shock therapy is usually painful and requires 
anesthesia as well as cardiac monitoring for patient comfort 
and safety. Thus, it cannot be applied with great frequency and 
requires that patients have the ability to maintain sinus rhythm 
for prolonged periods. Interventions such as defibrillation 
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drug regfmeu, there was no AT recurrence in any patient com- 
pared with five recurrences in 12 patients during single-site 
wing (P = O&3)3). The mean (&SD) arrh$bmia-free interval 
before pacing (14 I 14 days) was prolonged ith dual- (89 -C 7 
days, p < O.ooOl) and single-site pacing (76 & 27 days, p < 
O.OO!H). Symptomatic AF episodes showed a de&&g trend 
during dual- and single-site pacing compared with those during 
the preimplantation period (p = 0.10). Mean antiarrbythmic drug 
use for all classes decKned from 4 + I.9 drugs befare implantation 
to 1.5 -C 0.5 (p < 0.01) drags after implantation. Twelve (8%) of 
15 patients remained in atria1 paced rhythm at 13 -C 3 months. 
ConcMo~~. We conclude that multisite right atria1 pacing is 
feasible, etfective and safe for long-term application. Atrial pacing 
significantly prolongs arrhythmia-free intervals in patients with 
drug-refractory paroxysmal AF. Dual-site right atrial pacing may 
offer additional benefits and should be considered either as the 
primary mode or in patients unresponsive to single-site pacing. 
----_l_l 
therapy are usually withheld after a few attempts in most 
patients with recurrent AF. As a result, chronic A!? ensues. 
The etfcacy of demand atria1 pacing in reducing the frequency 
of recurrent AF has been suggested (4) in some patient groups 
with bradycardia-dependent AF. &atria1 pacing has been 
reported (5) to be associated witn low recurrence rates of atria1 
Butter and fibrillation in patients with severe interatrial con- 
duction disturbances. However, no prospective study has ver- 
ified the benefits of single- or dual-site atria1 pacing in un- 
selected patients with AF. Even more uncommon is a 
quantitative assessment of this benefit. Although atrial defi- 
brillators are being considered to revert recurrences of AI?, 
shock therapy remains painful. Reducing AF recurrence rates 
is essential to successful use of such devices. Quantitative 
assessment of arrhythmia-free intervals bears directly on their 
feasibility. 
We recently developed and applied a novel technique of 
dual-site atria1 pacing wholly from the right atrium, and 
applied it to an unselected consecutive series of patients with 
drug-refractory AE A prospective crossover study was per- 
formed that compared recurrence of arrhythmia ia a dual-site 
right atria1 pacing mode with single-site high right atria1 pacing 
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as well as in each pacing mode with a lead-in control period. 
The study design was used to evaluate the comparative and 
absolute value of either pacing method. The clinicai results of 
this study are reported herein. 
Patient selection. Patients inciuded in this report fulfilled 
the following criteria: 1) They had symptomatic drug- 
refractory AF; 2) all patients had to have experienced two or 
more episodes of sustained AF in the 3-month period before 
device insertion; 3) coexisting bradyarrhythmias in the absence 
or presence of drug therapy requiring rate support were 
present; 4) written informed consent for insertion of two atria1 
leads was obtained. 
Study design. Patients with symptomatic refractory AF 
despite antiarrhythmic drug therapy were fully evaluated for 
individual recurrences of arrhythmia over the YO-daf period 
before pacemaker insertion. This period was the lead-in drug 
treatment phase performed on a retrospective basis (Fig. 1). A 
comp!ete record of each documented episode of onset, dura- 
tion, treatment and termination was obtained. Consecutive 
consenting patients meeting enrollment criteria underwent 
implantation of two atria1 leads and one ventricular lead 
connected to a dual-chamber rate-responsive pacemaker. 
Atria1 pacing was performed at implantation from the high 
right atrium and coronary sinus ostium locations individually 
and in the dual-site right atriai pacing mode. 
Study definitions. The following definitions were used: 1) 
paru~~~~~zl arrhytknia = sustained arrhythmic episode >30 s 
in duration, spontaneously terminating before 57 days; 2) 
chmic arrhythmia = sustained arrhythmic episode >l month 
in duration with a history of episodes ~7 days in duration; 3) 
sustaimd arrhythmia = arrhythmic episode 230 s in duration; 
4) recuflence = electrocardiographicahy documented episode 
of sustained AF or recurrence of symptoms associated with 
previously electrocardiographically documented AI?. 
Study prc,Cocol. Implantation variables for pacing thresh- 
old, sensing and Iead impedance were obtained for each atria! 
site, in the dual-site mode and at the right ventricular apex. 
After device implantation, concomitant antiarrhythmic therapy 
was established for prevention of AF. Early recurrences of AF 
were evaluated for compliance with the prescribed pacing and 
drug regimen as well as the ability to maintain continuous 
atria1 pacing. Failure to comply or inability to maintain con- 
tinuous atria1 pacing resulted in adjustment of the drug 
regimen. Patients were programmed to the dual-site pacing 
output using polarity programming with the pacemaker. 
DDDR pacing WZiS used with a lower rate limit of $0 or 90 
beatsimin to ensure consistent atria1 pacing at rest. Rate 
response was clinically selected to ensure atrial pacing during 
activity. 
After hospital discharge: patients entered the crossover 
trial. Dual-site right atria1 pacing was programmed for the 
initial 90 days and drug therapy continued (combination 
therapy phase 1). At the completion of this period, consenting 
patients underwent device reprogrxxzzing to single-site high 
right atria1 pacing alone for the next 90 days (combination 
therapy phase 2). Patients with sustained recurrences despite 
compliance with the drug and pacing regimen were deemed to 
have completed the individual phase. They underwent eardio- 
version and reprogramming to the other pacing mode and 
entered the next phase of therapy. 
The primary end points were the number of patients with 
recurrence of AF and the time interval to the first sustained 
recurrence of ,4F despite compliance with the treatment 
regimen in the lead-in drug phase as well as each combination 
treatment phase. Secondary end points anaiyzed symptom-free 
intervals, antiarrhythmic drug therapy requirement and need 
for cardioversion. An additional analysis of these intervals was 
performed that included the drug optimization period with 
implantation as the onset of phase 1. The safety of the 
technique was assessed using standard categories of morbidity 
and mortality for the perioperative 30-day period as well as for 
the longer term follow-up for each combination treatment 
phase. 
Device implantation. Standard techniques for insertion of 
a dual-chamber pacemaker system were used. Percutaneous 
subclavian vein cannulation as well as cephalic vein isolation 
was attempted in all patients. Subclavian vein entry was 
necessary in all patients for one or more leads. The right 
ventricular apical lead (Medtronic model 5024 or 4058, 
Medtronic Inc.) was positioned first under fluoroscopic guid- 
ance. The first atria1 pacing electrode (Medtronic model 40%) 
was then positioned using a curved stilette with primary and 
secondary curvatures. Initially, the lead was passed into the 
coronary sinus under fluoroscopy and the lead position verified 
by sensed electrograms and paced electrocardiographic (EGG) 
configuration. The lead was then withdrawn to the coronary 
sinus ostium, and a secondary tip curvature of the stilette used 
to lodge it at the rim of the ostium, generally posteriorly. The 
lead was fixed at this site, and pacing and sensing thresholds 
were obtained. Paced P wave configuration was consistent with 
ostial pacing in this location (inverted P waves in leads II, III 
and aVF with a shorter PR interval than sinus rhythm). The 
second atria1 lead (Medtronic model 4058) was then passed 
and fixed in the high right atrium, usually in the right atria1 
appendage under fluoroscopic control, In postoperative surgi- 
cal patients with an amputated appendage, it was fixed in the 
high lateral right atrium. Bipolar pacing thresholds were 
obtained for all three leads. The two atria1 lead tip electrodes 
were then cross connected to form a bipole using a Medtronic 
model 5866-3SM Y connector with the high right atria1 lead as 
the cathodal electrode and the coronary sinus lead as the 
anodal electrode. Bipolar pacing variables in the dual-site 
atria1 pacing mode were then obtained. The right ventricular 
lead was inserted in the ventricular port of a Medtronic model 
7086 Elite II DDDR pacemaker (Fig. 1). The in-line bipolar 
lead from the Y connector was inserted into the atria1 port of 
the pacemaker. The pulse generator was then placed in a 
prepectoral pocket and the pocket closed using standard 
techniques. 
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Figure I. .A, Chest nldiograph (posteroanterior view) of the pace- 
maker generator and the three pacing/sensing leads. The ventricular 
kad is seen with its tip at the apex of the right ventricle. The ka atria1 
leads are seen at the right atria1 appendage (superior lead} and at the 
coronary sinus ostimn (inferior lead). B, Lateral view of the pacing 
system. The coronary sinus ostium lead is located posteriorly acd 
:-C.-z...,... .L2.., :. ..__.& 
Using the bipolar pacing mode from the pulse generator, 
simultaneous dual-site atria1 pacing using the tip electrodes of 
both atria1 leads could be established and was electrocardio- 
graphically verified. The paced P wave was hiphasic in config- 
uration and had a terminal negative component in the ink&~ 
leads. In the pro~rarn~~a~le unipoiar mode, single-site atria1 
pacing from the high right atrium could be established. On 
completion of the procedure, the pacemaker was programmed 
to bipolar atria1 and venl:icular pacing in the DDDR mode. 
The lowest atria1 and ventricular rate was programmed to SO or 
90 beatsimin to establish continuous pacing at rest. Rate 
response was selected at levels likely to establish continuous 
pacing during exercise. Drug regimen selection was then 
performed in the postimplantation period to maintain contin- 
uous atria1 pacing. Drugs used were based on previous patient 
experience and utilized previously toierated but ineffective 
agents for AF suppression. 
Patient foIIow-up. Patient follow-up after haspitsl dis- 
charge was designed to assess arrhythmia control and device 
system performance. Postoperative clinic visits with a standard 
124ead ECG were scheduled after hospital discharge at 1 
week, I month, 3 months and every 3 months thereafter. 
Patients were instructed to report symptoms of palpitations, 
chest pain, dyspnea or other symptoms consistent with arrhyth- 
mia recurrence in interval periods. Patients with symptoms 
were provided transtelephonic event monitors. Twenty-four 
hour ambulatory ECG monitoring was performed after 1 
month of each combination therapy in all patients. Device 
system performance was assessed using monthly transtele- 
phonic monitoring and device interrogation and assessment of 
all pacing variables at each clinic visit, Effective single- and 
dual-site atrial pacing was confirmed using the ECG contigu- 
ration of the P wave as weil as sensed electrogram variables. 
Statistical analysis. A minimal follow-up period of 1 year 
was required of all study patients. Patients were censored from 
follow-up at death or device system explantation. Comparison 
of primary and secondary end points was performed using 
appropriate statistical tests (e.g., paired f test, McXemar’s test 
and, for repeated measures analysis of variance (ANOVA)? the 
Wks lambda statistic). 
Patients. Fifteen patients (nine men, six women; mean 
[SXJJ age 68 i- I2 years? range 41 to 81) with AI? and 
bradyarrhythmias warranting permanent pacing were enrolled 
in the study. Coronary artcry disease was presern in six 
patients, hypertension in one, congenital heart disease in one 
and cardiomyopathy in two. The primary indication for pacing 
was sick sinus syndrome in six patients, drug-induced brady- 
arrhythmias in three, conduction system disease in thr& and 
neurocardiogenic syncope due to bradycardic mechanisms in 
three. The mean left atria1 diameter on ec~lo~ardi~~graphi~ 
measurement was 3.7 i 0.6 cm, and the mean left ventricular 
ejection fraction was 49 F 12% (Table 1). 
PreviousIy unsuccessful drug trials of class I and III antiar- 
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‘Fabie I. Den~ographic and Clinical Data, Antiarrhythmic Drug Use Before and After Pacemaker Implanttntian and Clinical Outcome With .Respect to 
.4&3&rnkt Recurrence in 15 Study Patients - 
Arrhythmia LA Postor, Outcome 
Pt No./ Age Chid Frequency Pmions Cardiac Diamelel LVEF ?a.cemakei Drug 
Ger~dcr (Yr) Arrhythmia (episodesimo) Drum Used Disease (mm) i%) Indication xxrapy Philse 1 Phase 2 
l/M 41 PAF 1 S,D.PCAPR NOllC 28 6c -iii PR SR SR 
2/M 73 ?AFL/AF 4 S.A,PCADIG,PP CAD 38 36 AVB S,DIG,PP SR SR 
3/M 19 CAF 30 PCA,D,DIG DCM 38 is AVB PCA,DIG SK AF 
4/F 55 p,Q 8 Q,PCA,D,D!G None 30 60 sss DIL SR SK 
5/F 15 P‘4FL 30 Q,PCA,DIG.V CAD 35 50 SSS NONJZ SIX Rcfuzed mode than g e 
6/F 11 CAF 30 S.PCA,PR,DIG m 50 @.. DB s SR SK 
ml 17 PAFUM 1 NOtliZ NOW 32 32 CSH None SR Refid mcndc change 
8/F 16 PAFL’AF 30 PCA.Q,S,D,PR,DIG None 35 50 SSS D.DII,DG SR AF 
9/M 12 PAF/AFL 2 D,Q,PP CAD 38 SO sss D,DIG SR AF 
I OM 57 PAFL 1 Q,PCA,V,D HCM 3s so HCM ME,V SR SR 
11/M 63 PAFIIAF ‘cl D.PCA,PRS CiW 40 40 sss 5 SR AF 
l&F ffi PAFUAT 30 PCA,D,V.DIL,ME cm 40 50 DB ME SR AT 
13/M 81 I’AFL 2 ME CAD 40 39 Ncs None SR SK 
14?4 51 PAF 1 PP None 36 60 AVB I SK SR 
15127 12 PAF 30 A,PCA,-J,DIG:D,PR CAD 50 50 DB kV.DG SR Refused mode change - -- 
A = amiodarone; AF = atrial bihbrillation; Arrhythmia Frequency = number of sustained symptomatic episodes/month before pacemaker implantation AT = 
atrial tachycardia; AVB = atriovcntricuiar block CAD = coronary artery disease: CAF = chronic atrial fibrillation; CHD = congenital heart disease; CSH = carotid 
sinus syncape; D = disopyramide; DB = drug-induced bradycardia; DCM = dilated cardiomyopathy; DIG = digoxin; DIL = dihiazem; F = female; WCM = 
hypertrophic cardiomyopathy; HT = hypertension; LA = left atriab LVEF = left ventricular ejection fraction; M = male; ME = metoprolol; NCS = neurocardiogenic 
syncope; PAF = paroxysmal atrial hiirillation; P.4FL = paroxysmal atria1 flutter; PCA = procainamide; Postop = postoperative; PP= propanolol: PR = propafenone: 
Pt = patient; Q = qukidine; S = sota!ol; SK = sinus inythm; SSS = sick sinus syndrome: V = verapamil. 
rhythmic agents for AF averaged 2.7 rt 1.6 agents. All patients 
had frequent recurrent AF, and 14 had one or more docu- 
mented episodes of AF within 1 month before pacemaker 
implantation. The average interval from the last documented 
episode of Al? to implantation was 10.6 + 21.7 days. Before 
implantation, the mean frequency of AF episodes, according to 
documented KG strips, was 1.5 t 1.7 episodes/week; the 
mean arrhythmia-free interval was 14 2 14 days, and the mean 
frequency of symptoms (presyncope, dyspnea or palpitations) 
was 3.1 ? 4.1 episodes/week. Antiarrhythmic agents used in 
these patients before pacemaker insertion included quinidine, 
propafenone, disopyramide, sotalol, amiodarone and procain- 
amide. Digoxin and class II or IV agents had also been used in 
combination with class I or III drugs in selected patients. 
Combinations used verapamil (two patients), diltiazem (two 
patients) and beta-adrenergic blocking agents (four patients) 
with clnss I or III drugs. All patients received a Medtronic 
model ‘7086 Elite II pacemaker and model 4058 or 5024 leads. 
Subclavian vein access was used alone in 4 patients, whereas 
combined subclavian and cephalic vein insertion was used in 
11, Figure 1 is an illustration of the device system in situ. Note 
the three electrode systems with the location of the atria1 leads 
in the anterior high right atria1 and the posterior coronary 
ostial sites. A Y connector is seen in the pectoral pocket with 
the generator. 
Three patients were discharged, without ant&rhythmic 
drug therapy, in the DDDR pacing mode using dual-site atria1 
pacing alone for AF prevention. Twelve patients were dis- 
charged with concomitant antiarrhythmic therapy that in- 
cluded class IIIA agents in four patients, class IC agents in one, 
class II agents in five, class IIf %gc,ats in three, class IV in fi;e 
and digoxin in four. Drug combinations were used in six 
patients. Three patients initially refused mode switching from 
the dual-site to the single-site atria1 pacing mode at 3 months 
of fotiow-up because of a perceived improvement in clinical 
status. All patients are receiving warfarin or aspirin therapy. 
Pacing system performance, The mean pacing threshold at 
the high right atrium at implantation was 1.18 + 0.32 V, and 
that at the coronaly sinus ostium was 1.37 + 0.25 V {p = 0.06) 
at a pacing palse width of 0.5 s. The sensed P wave amplitude 
at the high right atrium was 2.‘Y8 i 1.71 mV, and that at the 
coronary sinus ostium was 2.26 rt 0.82 mV (p = 0.35). The 
mean pacing threshold in the dual atria1 pacing mode was 
1.56 I 0.52 V, significantly higher than that at the high right 
atrium (p = 0.02) but not at the coronary sinus nstium (p = 
0.22) (Fig. 2A). The sensed P wave amplitude in dual-site 
mode was 2.58 t 0.95 mV. The mean pacing threshold in the 
right ventricle was 0.61 rt 0.24 V, and the sensed R wave 
amplitude was 14.6 t 6.5 mV. 
Figure 2B shows the atria1 pacing thresholds of the lead 
system at the last (mean 8 months) follow-up visit. Note that 
long-term pacing thresholds are higher in the dual-site mode 
(p < 0.01). The pacemaker pulse generator was programmed 
to a low rate of 80 btats/min (14 patients) or 90 beatslmin 
(i patient). In one additional patient, the device initially pro- 
grammed at 80 beats!‘min wa:s reprogrammed to the higher rate 
during follow-up. The DDDR mode was used in all patients 
with an activity threshold of medium in 14 patients and low in 
1. The rate response used was seven in all patients. The upper 
rate limit was 130 or 140 beats/min in all patients. 
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Figure 2. A, Atria1 pacing thresholds in volts at implantation in the 
right atrial appendage (dotted column), coronary sinas ostium (solid 
column) and the dual-site pacing mode (hatched column). The pacing 
threshold with the dual-site mode is significantly higher than that for 
the right atria1 appendage. B, At a mean follow-up period of 8 months, 
the pacing threshold with dual-site pacing is significantly higher than 
that at the eight atria! appendage. 
Complications. Marked elevation of the right ventricular 
threshold was observed in two patients at 9 and 43 days after 
implantation, respectively. The lead was observed to be in the 
right ventricular apex in both patients and required rcposition- 
ing for better thresholds in both instances. There was one atria1 
lead dislodgment from the high right atrium in a postoperative 
cardiac surgical patient. This lead was repositioned in the 
lateral high right atrium. There was no coronary sinus ostial 
lead dislodgment. One patient had pneumothorax with subcla- 
vian puncture requiring evacuation. One patient required 
pacemaker pocket revision due to her asthenic habitus. Sub- 
sequently, she experienced pocket infection after a surgical 
procedure at a contiguous axillary location, resulting in device 
explantation 7 months after implantation. One atria1 lead was 
noted to oversense and was determined to have a loss of 
adhesive coating over the set screw in the Y connector, 
resulting in oversensing of muscular signals and requiring 
reinsulation with medical adhesive. 
Arrleythmia recurrence. Four patients had documented 
recurrences, usually transient, of sustained Al? in the dual-site 
pacing mode during the drug optimization period, Spontane- 
ous termination of recurrent AF occurred in three patients, 
and direct current (DC) cardioversion was required in 
one. These patients either had no antiarrhythmic therapy (one 
Figure 3. Mean arrhythmia-free iniervals (532) in days with dual-site 
[hatched column) and high right atria1 pacing (dotted column) and the 
preimplantation lead-in period (solid column). There is a sigGficant 
increase in the arrhythmia-free interval after implementation of atrial 
pacing with both the dual-site and high right atria! pacing modes, and 
the arrhythmia-free interval is greater with the dual-site than the high 
right atria1 mode. 
patient) or were taking disopyr&de (three palientsj. In one 
patient, faGme to maintain continuous atria1 pacing was noted. 
In these four patients a ditTerent but previously ineffecrive 
antiarrhythmic drug was then started {two patients), or the 
dose of the existing drug was increased (one patient), or the 
dosing schedule was altered (one patient) to achieve continu- 
ous atria1 pacing. W&ii &se modificarions, ali 15 patients were 
f&lowed up for a full 3 months on the optimized drug regimen 
to complete phase 1. There was no recurrence of AF in any 
patient during this period, The patients were then maintained 
on the same regimen in the single-site high right atria1 pacing 
mode in phase 2. Five patients experienced recurrent AF in 
this pacing mode, occurring 30 to 85 days after entering this 
phase. Using McNemar’s test, there is a statistically significant 
difference in the arrhythmia suppression between the two 
modes (p = 0.03) once the final drug plus device regimen was 
established. All 4 patients showing an early recurrence with 
device therapy alone or with low drug dosage experienced 
recurrert AF wiG the final drug plus device regimen selected 
in the high right atrial pacing mode. 
The mean arrhythmia-free interval in the initial drug and 
dual-site pacing mode was 77 f 26 days and was higher than 
the preimplantation arrhythmia-free interval (14 ? 14 days) or 
lhe time interval between the last documented AI: episode and 
device implantation (11 2 22 days). Repeated measures 
ANOVA for patients completing dual- and single-site pacing 
showed a statistically significant difference in mean 
arrhythmia-free interval between preimplantation, dual- and 
single-site values (Wilh lambda 0.03, p C: O.oOr,l). Analysis of 
paired differences showed that the arrhythmia-free interval 
(Fig. 3) for the optimized final drug and dual-site pacing mode 
(59 t 7 days) was also higher than the preimplantation 
arrhythmia-free interval (p < 0.0001) as well as the initial 
dual-site pacing mode {p < 0.03). Single-site pacir.g similarly 
had longer arrh~l~mia-tree intervals (76 5 27 days) than the 
preimplantation period (p < 0.0001). The arrhythmia frec- 
internals in the optimized drug plus device treatment mode 
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Figure 4. Patient symptoms with respect to arrhythmia before and 
after the implementation of atria1 pacing. There is a signticant 
decrease in patient symptoms (number of symptomatic atria1 Iibrilla- 
tion [AI?] episodes/per week) with both atrial pacing modes. However, 
there is no difference in symptomi-itic AF episodes between the hvo 
pacing modes. Symbols as in Figure 3. 
showed a trend to higher values for the dual-site mode than the 
single-site mode (p = O,lO), recognizing that either interval is 
limited by a maximum of 90 days by study design (Fig. 3 j. Thus, 
patients remaining arrhythmia free at the end of a given phase 
may actually achieve longer arrhythmia-free intervals in clini- 
cal practice with either mode. The postimplantation symptom- 
ate frequency for the unoptimized and optirnized dual-site 
mode (0.5 + 0.6 and 0.29 + 0.45 symptomatic episodes/week, 
respectively) showed a trend to lower values than the preim- 
ptantation frequency (3.1 t 4.1 symptomatic episodes/week, 
p = 0.09) for paired data (Fig. 4). There was no difference in 
symptoms between the dual- and single-site modes (0.29 rt 
0.45 vs. 0.47 t 0.48 symptomatic episodes/week, p = 0.56). At 
the completion of phase 1, 15 patients were in an atrial-based 
rhythm, whereas 7 of 12 patients with mode-switched devices 
were in this rhythm at the end of phase 2 (p < 0.05). 
Cardioversion for termination of recurrent AF was necessary 
in one patient in phase 1 and four patients in phase 2 (F < 
0.05). Atrial-bar;ed pacing was successfully reestablished with 
the dual-site mode in phase 3 in two of the five patients with 
recurrences in phase 2. 
Drug therapy. Figure 5 shows the mean number of antiar- 
rhythmic drugs used in the study patients before and after 
initiation of atria1 pacing. There is a significant decline in the 
total mean drug usage. This decline is largely due to a decline 
in the use of class I and III drugs. Three patients received no 
drug therapy; six patients had single-drug therapy; and the 
remaining six patients were recei&zg one class I or III drug in 
combination with digoxin, a calcium channel blocking agent or 
a beta-blocker. Of these six patients, three were taking a total 
of two agents, and three were taking three agents. 
Discussion 
Atriall fibrillation recurrences in paced patients. Preven- 
tion of AF by nonpharmacologic methods is now being widely 
investigated. Surgical ablation has been effective in the pre- 
vention of recurrent AF in selected patients but carries the risk 
of morbidity, atria1 hemodynamic dysfunctio:, and even mor- 
* Dp,, BEfORE PACING APTER PACtNO 
1 I 
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Figure 5. Comparison of ant&rhythmic drug use before and after 
atria1 pacing. Solid columns indicate drugs of all classes, wbereas 
hatched columns represent class I and III antiarrhythmic drugs. There 
is a significant decrease in the mean number of drugs used after 
implementation of atria1 pacing in all classes and classes 1and Iii. 
taiity (6) Catheter ablative methods remain largely investiga- 
tional in AF (7,8). Pacing techniques have been applied for 
suppression of atria1 and ventricular premature beats as well as 
sustained tachycardias (9-12). Fisher et al. (9) noted the 
suppression of ventricular premature beats with ventricular 
pacing in a prospective clinical trial. However, king-term use of 
zttirachycardia pacing iilethods has been large ly restr i&d to 
reversion of sustained atria1 and ventricular taehycardias (13- 
15). Demand atria1 pacing can reduce the frequency of recur- 
rent AF in patients with sick sinus syndrome (4,16,17). During 
long-term follow-up, patients with sinus node dysfunction 
treated with single-site atria1 or ventricular pacing had an 
incidence of AF that varied from 5% to 7% for atrial pacing 
versus 32% to 47% for ventricular pacing at 3 to 5 years 
(16-H). Patients with concomitant supraventricular arrhyth- 
mias and sick sinus syndrome in the same series had siguifi- 
cantly higher rates of recurrence of AF, ranging from 9% to 
41% with atria1 pacing during the same follow-up, These 
findings were extended in a prospective study where the 
incidence of AF in patients with sinus node dysfunction alone 
was 18% with atria1 pacing and 40% with ventricular pacing at 
5 years (19). 
The benefit of cardiac pacing in an unselected cohort with 
drug-refractory AF and bradycardias, as in our study, is 
unknown. In drug trials (20) using a cohort with ‘Frequent 
drug-refractory AF, a mean arrhythmia-free interval of 3 days 
was seen with placebo treatment and increased to 15 days with 
flecainide therapy. In another drug trial in this cohort, Pritch- 
ett et al. (21) reported that only 10% of their patients taking 
placebo and 25% taking propafenone were free of recurrence 
of AF at the go-day follow-up visit. 
&IFisite atrial pacing: technical and electropbysioiogic 
considerations. Multisite pacing methods for arrhythmia sup- 
pression have been applied in ventricular arrhythmias with 
limited success (22). More recently, simultaneous biatrial 
pacing has been reported (55) to be associated with !ow 
recurrence rates of atria1 flutter and fibrillation in patients with 
severe interatrial conduction disturbances, often seen with 
hypertrophic cardiomyopathy. However, technical difficulties 
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with coronary sinus iead placement and maintenance required 
in this pacing mode and the select patient cohort could limit its 
general applicability. The conceptual advantages of the right 
atria1 approach to multisite pacing are in part hugely technical, 
with the potential for reduced lead dislodgment. This was 
indeed validated with the absence of coronary ostial lead 
dislodgment in the present initial series over a follow-up period 
>1 year. EiectrophysioIogic advantages could also exist. The 
isthmus between the tricuspid valve and inferior vena cava is a 
key slow conduction zone in type 1 atrial flutter, which may in 
some patients precede development of AE. The triangle of 
Koch has been suggested by anatomic studies to have anatomic 
and electrical continuity with atria1 fibers from the right and 
left atrium contributing to the inter&al septum (Rossi L, 
personal communication, 1994). These regions are considered 
by many to be a key zone for arrhythmogenesis in patients with 
AF. Simultaneous electrical stimulation at the high right 
atrium and coronary sinus ostium can eliminate dispersion of 
atria1 refractoriness; abbreviate right and left atria1 activation; 
and eliminate, reduce or modify areas of delayed activation 
(23,24). The initiation of AF may require both electrical 
conditions of dispersed refractoriness as well as anatomic sites 
of conduction block in one or both atria to generate multiple 
wavelets (25). We analyzed the immediate electrophysiologic 
effects of dual-site right atria1 pacing and observed abbrevia- 
tion of P wave duration and regional atria1 activation times in 
both the right and left atria (23,24). Suppression of inducible 
AF in patients with marked dispersion of refractoriness has 
also been observed in these short-term studies (23). These 
eiectrophysiologic findings may provide the theoretic basis for 
reduced AF recurrence rates during dual-site atria1 pacing and 
perhaps even during single-site pacing modes. 
Arrhytiunia-free intervals in atria1 pacing. The ability of 
atria1 pacing to increase arrhythmia-free intervals in patients 
with drug-refractory paroxysmal AF has been established by 
our data. The relativeiy few patients with chronic AF in this 
initial experience does not permit the same conclusion in this 
patient cohort. Our results also clarify the often reported 
observation of reduced recurrence of AF in atria& paced 
patients with sick sinus syndrome with coexisting atria1 arrhyth- 
mias. Interestingly, there was no difference in recurrence of AF 
in patients with primary sinus node disease and other indica- 
tions for cardiac pacing in this series. In fact, most AF episodes 
do not commence with sinus or ventricular pauses in Halter 
monitor analyses. This would imply that overdrive atria1 pacing 
had a primary effect on the atria1 substrate rather than simply 
prevention of atria1 or ventricuiar bradycardic pau.ses that may 
precede bradycardia-dependent AF (26). The maximal possi- 
ble arrhythmia-free interval in phase 1 and 2 was 90 days. The 
time dependence of AF recurrence was recognized in the study 
design. The majority of AF recurrences occur within the first 3 
months in most drug &dies (20,21). Our measurements of 
arrhythmia-free intervals are clearly underestimates bee&use 
many patients would have and have had longer arrhythmia-free 
periods. We chose the 3-month period as a watershed with the 
view that more than four cardioversions/year would be unac- 
ceptable in terms of patient tolerance with an implantable 
atria1 defibrillator or certainly with external DC cardioversion. 
In addition, electrophysiolagic and mechanical remodeling of 
the atrium to the extent feasible iu these patients may be 
largely completed by this time (27). This could reduce propen- 
sity to Al: in the lo;lg term. The dual-site mode was utilized 
first in an attempt to test the eficacy of this pacing mode in the 
highest density period of arrhythmia recurrence. Ahhough 
such a design actually favors a better result for the single-site 
mode, the data in this study suggest a distinct benefit for the 
dual-site mode. This would further strengthen the conclusions 
regarding incremental benefit of multisite pacing over single- 
site pacing. A marked decrease in antiarrhythmic drug use is 
also important. Reduced use of class I agents could have a 
favorable effect on survivai. Digoxin and ciass II drugs were 
often needed to establish continuous atria1 pacing. The virtua: 
elimination of cardioversion during follow-up and the absence 
of readmittance to the hospital in all but two patients for 
recurrence of AF also supports the benefit of this nonpharma- 
cologic approach to the prevention of AF. Atria1 pacing modes 
may significantly contribute to the feasibility of wide apphca- 
tion of an implantable atrial defibrillator or the use of dual- 
chamber pacemakers for the management of AF. 
Study limitations. The lead-in period may underestimate 
recurrence of arrhythmias because of the requirement of ECG 
documentation. The subseqtteat phases used either ECG end 
points or symptoms with previous ECC validation. However, 
some drugs, most prominently sotalal, have been reported (28) 
to reduce symptoms associated with recurrence. Thus, in the 
absence of continuous EGG monitoring, we canuot exciude 
brief asymptomatic recurrences while a control arm of drug 
therapy was considered. The increased study complexity and 
previous demonstration of drug refractoriness raised concerns 
about submitting patients to the risk of recurrence of AF and 
repeated cardioversion. The methodology used in the present 
study parallels the standard design of many drug t&Is. Brief 
asymptomatic episodes are also unlike!y to prompt hospital 
admission, Finally, treatment algorithms in implantable de- 
vices seek tc avoid intervention in transient and minimally 
symptomatic atria1 arrhythmias. Thus, our study data should 
reflect events needing clinical intervention. The lack of random 
assignment to each pacing mode may favor one mode over 
another. 
Conclusions. Multisite right atria1 pacing is feasible and 
safe and effective for long-term application. Single- and dual- 
site right atria1 pacing significantly prolongs arrhythmia-free 
intervals in patients with drug-refractory paroxysmal AF. Dual- 
site right atria1 pacing may offer additional benefits and should 
be considered either as the primary mode or in patients 
unresponsive to single site pacing. Technical and technologie 
deveiopment to improve its ease and application is needed. 
Further study of the electrophysiologic changes associated with 
this pacing mode are warranted.. S:rch pacing modes may be 
valuable as stand-alone therapy or as an adjunct to defibriha- 
tion therapy in implantable device therapy for AF, 
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